Search results
Results from the WOW.Com Content Network
Cipla sells active pharmaceutical ingredients to other manufacturers as well as pharmaceutical and personal care products, [20] including the anti-depressant escitalopram oxalate, lamivudine, and fluticasone propionate. [21] Cipla is the world's largest manufacturer of antiretroviral drugs. [20] [22]
A BBB-accredited company agrees to abide by a set of accreditation standards BBB says are "attributes of a better business." These include honesty in advertising, transparency, and responsiveness ...
Dig a bit deeper into the BBB's report and a picture emerges of which sorts of business are generating the most inquiries: Topping the list are roofers, with more than 3 million inquiries in 2011 ...
Cipla, India's No.3 generic drugmaker by sales, reported a better-than-expected quarterly profit on Friday, boosted by strength in its key domestic and North American businesses. The results come ...
In 2023, the Indian government's Chief Economic Advisor, V Anantha Nageswaran questioned India's sovereign credit rating of BBB- by S&P and Baaa3 by Moodys and called for a review of the big three's rating methods. [14] In January 2024, CareEdge Ratings issued its Sovereign Ratings Framework for public consultation. [15]
India's revenue from pharmaceutical exports was $25.3 billion in the 2022-2023 financial year. [7] In terms of the global market, India currently holds an accountable share and is known as the pharmacy of the world. [9] The country is the largest global supplier of generic medicine. [10] India produces more than 50% the world's vaccines. [11]
Lupin's businesses encompass the entire pharmaceutical value chain, ranging from branded and generic formulations, APIs, advanced drug delivery systems to biotechnology. . The company's drugs reach 70 countries [22] with a footprint that covers advanced markets such as USA, Europe, Japan, [23] Australia as well as emerging markets including India, the Philippines and South Africa to name a
HYDERABAD/BENGALURU (Reuters) -Cipla, India's third-largest generics drugmaker by sales, beat first-quarter profit estimates on Friday as it reported higher sales in its North America market ...